Kilitch Drugs (KILITCH)
STALWARTFairStock Score: 8/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹159.95 |
| Market Cap | ₹565.5 Cr |
| P/E Ratio | 21.71 |
| ROCE | 15.67% |
| ROE | 12.57% |
| Dividend Yield | 0% |
| Profit Growth | -25.67% |
| Debt/Equity | 0.32 |
| Sales Growth | -4.2% |
| Promoter Holding | 63.77% |
| 52-Week Range | ₹117.25 — ₹250 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹136.19 |
Kilitch Drugs trades with a P/E ratio of 21.71, ROCE of 15.67%, ROE of 12.57%, profit growth of -25.67%, debt-to-equity of 0.32. The FairStock Score of 8/100 flags concerns across multiple fundamental dimensions that investors should examine carefully.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer